SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184247

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184247

Liquid Biopsy-Guided Therapy Switching Market, By Biomarker Type, By Liquid Biopsy Technology, By Cancer Type, By Therapy Switching Approach, By End User, By Geography

PUBLISHED:
PAGES: 250 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

Liquid Biopsy-Guided Therapy Switching Market is estimated to be valued at USD 1.24 Bn in 2026 and is expected to reach USD 2.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.9% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 1.24 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 9.90% 2033 Value Projection: USD 2.40 Bn

Liquid biopsy guided therapy switching is a new precision oncology strategy based on circulating tumor DNA (ctDNA), circulating tumor cells and other biomarkers in blood and body fluids to monitor tumor changes and guide therapy switching. Unlike conventional tissue biopsies, it enables minimally invasive, repeated assessment of emerging resistance mutations, disease progression, and treatment response.

Specific therapies and immunotherapies are creating the need for timely biomarker-based treatment decisions, and the market is gaining momentum. Advances in next-generation sequencing, digital PCR and bioinformatics are helping improve mutation detection and molecular monitoring, allowing more tailored approaches to cancer treatment and enabling clinicians to adjust therapies as cancers evolve.

Market Dynamics

The global liquid biopsy-guided therapy switching market is driven by the growing incidence of cancer, increasing demand for customized oncology, and technological advancements in next-generation sequencing (NGS), digital PCR, and circulating tumor DNA (ctDNA) analysis. Regulatory approvals of liquid biopsy companion diagnostics and increasing clinical evidence of mutation-guided treatment changes further encourage the adoption in oncology centers and diagnostic laboratories.

However, a number of constraints are present in the market, such as high testing costs, inconsistent reimbursement and variability in testing protocols and differences in regulatory requirements across countries. Nevertheless, significant opportunities exist within the AI-driven analysis of multi-omic data, improved detection of emerging treatment resistance, and expansion of liquid biopsy applications across additional cancer types, enabling more precise and adaptive treatment decisions.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global liquid biopsy-guided therapy switching market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Guardant Health, Inc., F. Hoffmann-La Roche Ltd., Foundation Medicine, Inc., Labcorp Holdings Inc., Tempus AI, Inc., Caris Life Sciences, Inc., NeoGenomics Laboratories, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., and Exact Sciences Corporation
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global liquid biopsy-guided therapy switching market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liquid biopsy-guided therapy switching market

Market Segmentation

  • Biomarker Type Insights (Revenue, USD Bn, 2021 - 2033)
  • ESR1 Mutations
  • EGFR Mutations
  • KRAS Mutations
  • Other Actionable Biomarkers
  • Liquid Biopsy Technology Insights (Revenue, USD Bn, 2021 - 2033)
  • Next-Generation Sequencing (NGS)
  • Digital PCR (dPCR/ddPCR)
  • PCR-Based Assays
  • Cancer Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Others
  • Therapy Switching Approach Insights (Revenue, USD Bn, 2021 - 2033)
  • Switching Treatment Before Clinical Progression Based on Molecular Resistance
  • Switching Treatment at Clinical or Radiographic Progression
  • Switching Treatment Based on Molecular Response or Emerging Biomarkers
  • End User Insights (Revenue, USD Bn, 2021 - 2033)
  • Hospitals and Oncology Centers
  • Diagnostic and Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Others
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
  • Guardant Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine, Inc.
  • Labcorp Holdings Inc.
  • Tempus AI, Inc.
  • Caris Life Sciences, Inc.
  • NeoGenomics Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Exact Sciences Corporation
Product Code: CMI10313

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Liquid Biopsy-Guided Therapy Switching Market, By Biomarker Type
    • Global Liquid Biopsy-Guided Therapy Switching Market, By Liquid Biopsy Technology
    • Global Liquid Biopsy-Guided Therapy Switching Market, By Cancer Type
    • Global Liquid Biopsy-Guided Therapy Switching Market, By Therapy Switching Approach
    • Global Liquid Biopsy-Guided Therapy Switching Market, By End User
    • Global Liquid Biopsy-Guided Therapy Switching Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Biomarker Type Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Market Opportunities
  • Industry Trends

4. Global Liquid Biopsy-Guided Therapy Switching Market, By Biomarker Type, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • ESR1 Mutations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • EGFR Mutations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • EGFR Mutations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Other Actionable Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Liquid Biopsy-Guided Therapy Switching Market, By Liquid Biopsy Technology, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Next-Generation Sequencing (NGS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Digital PCR (dPCR/ddPCR)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • PCR-Based Assays
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Liquid Biopsy-Guided Therapy Switching Market, By Cancer Type, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. Global Liquid Biopsy-Guided Therapy Switching Market, By Therapy Switching Approach, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Switching Treatment Before Clinical Progression Based on Molecular Resistance
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Switching Treatment at Clinical or Radiographic Progression
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Switching Treatment Based on Molecular Response or Emerging Biomarkers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. Global Liquid Biopsy-Guided Therapy Switching Market, By End User, 2021-2033, (USD Bn)

  • Introduction
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2022 - 2033
    • Segment Trends
  • Hospitals and Oncology Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Diagnostic and Reference Laboratories
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Pharmaceutical and Biotechnology Companies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

9. Global Liquid Biopsy-Guided Therapy Switching Market, By Region, 2021 - 2033, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Liquid Biopsy Technology, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapy Switching Approach, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Liquid Biopsy Technology, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapy Switching Approach, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Liquid Biopsy Technology, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapy Switching Approach, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Liquid Biopsy Technology, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapy Switching Approach, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Liquid Biopsy Technology, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapy Switching Approach, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Liquid Biopsy Technology, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Therapy Switching Approach, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Guardant Health, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-La Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Foundation Medicine, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Labcorp Holdings Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Tempus AI, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Caris Life Sciences, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • NeoGenomics Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • QIAGEN N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Exact Sciences Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!